Product Reports Resources Pricing Login Book a demo
COMPANY PROFILE

Enterprise Therapeutics

Request full access

Novel muco-regulatory therapies for respiratory diseases

Lewes, United KingdomFounded 2014Biotech & Life Sciences

About Enterprise Therapeutics

Enterprise Therapeutics is a clinical-stage biopharmaceutical company founded in 2014, dedicated to developing treatments for respiratory diseases with high unmet medical needs. The company was co-founded by Professor Martin Gosling from the University of Sussex, who also serves as the Chief Scientific Officer. Enterprise Therapeutics is headquartered in Brighton, UK, with offices at the Sussex Innovation Centre and in London.

The company's primary focus is on discovering and developing disease-modifying therapies that address the underlying mechanisms of mucus congestion in conditions like cystic fibrosis (CF), chronic obstructive pulmonary disease (COPD), and severe asthma. By targeting specific ion channels, these therapies aim to hydrate and clear mucus from the airways, which can reduce lung infections, restore lung function, and improve patients' quality of life. The business model centers on the research and development of a proprietary drug pipeline. The company has received significant backing from venture capital investors including Novartis Venture Fund, Versant Ventures, Forbion, and Panakes Partners.

A significant milestone was the acquisition of its TMEM16A potentiator portfolio, including the clinical-stage compound ETD002, by Roche in October 2020 for an upfront payment of £75 million. The company's lead program, ETD001, is a novel ENaC ion channel blocker designed for durable target engagement. In January 2024, Enterprise secured £26 million in a Series B follow-on financing to fund a Phase 2a clinical trial for ETD001 in cystic fibrosis patients who are ineligible for or not receiving CFTR modulators. The company also established an Italian subsidiary to expand its R&D and clinical activities.

Source: Dealroom company data

At a glance

Status
Operational
Founded
2014
Headquarters
Lewes, United Kingdom
Employees
12
Open positions
None listed
Dealroom signal
70.9/100
Industry
Health
Sub-industry
BioTechnology
Sector
Biotech & Life Sciences, Biotechnology, Respiratory, Health Diagnostics, Spinout, Disease, Biotech and Pharma, DT and LS, uk is8 life sciences, UKSU, UKSU2010
Business model
Manufacturing
Client focus
B2B

Funding history

8 recorded events

Company financing events and reported valuations.

Deal typeDateAmountValuationInvestorsSource
SERIES BOther financing Feb 2024 $26M $145M IP Group · Epidarex Capital · Panakès Partners · Forbion Capital Partners ↗
GRANTOther financing Oct 2019 $7.3M — Cystic Fibrosis Foundation —
Showing the latest 2 of 8 recorded eventsBook a demo for the full funding history →

Financials

Revenue, earnings and profit over time

Revenue, earnings and other financial measures where available. Years marked “E” are estimates.

Company filings, research estimates and Dealroom dataBook a demo for the full financial model →

Growth signals

Enterprise Therapeutics website traffic

Latest recorded traffic for Enterprise Therapeutics is 530 monthly website visits, down 42.4% over the last three months. Enterprise Therapeutics's team grew 0% over the past year.

Latest monthly visits530 3-month web change-42.4% 1-year team growth0%
Summary metrics are public; monthly history is available with a demoCompare with peers →

Similar companies

Closest operating peers by Dealroom taxonomy

Company identity and context are open; selected comparison metrics preview what is available on the platform.

Showing 8 of the closest matchesCompare every metric →

Investments and acquisitions

Capital deployed

Recent portfolio relationships for companies that also act as investors or acquirers.

Enterprise Therapeutics in the Lewes ecosystem

Live from Dealroom

The Enterprise Therapeutics office with the hot startups, most funded companies and investors around it. Hover or tap a pin.

Loading the map…

Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →

Investors

10 investors on the cap table

From Dealroom's funding and investor records, grouped by the round each investor first entered.

Seed1 investor entered at this stage

  • Cystic Fibrosis Foundation

Series A7 investors entered at this stage

  • Epidarex Capital
  • Imperial Innovations
  • Versant Ventures
  • Novartis Venture Fund
  • Forbion Capital Partners
  • IP Group
  • Panakès Partners

Other known investors2 additional known investors

  • Esher Sixth Form College
  • University of Aberdeen
Team profiled 9 named & role-tagged
Founders Hidden — book a demo/100 quality score
Key operators 3 quality Hidden — book a demo/100
Potential founders Hidden — book a demo likely future founders
Startup mafia Hidden — book a demo alumni-founded startups
Talent movements Hidden — book a demo in · Hidden — book a demo out past 12 months

Source: Dealroom Talent Intelligence.

Global footprint

Workforce and web traffic by country
Workforce by country
4 countries with
team presence
🇬🇧 United Kingdom72.7%
🇮🇹 Italy9.1%
🇨🇭 Switzerland9.1%
🇺🇸 United States9.1%
4 countries shown

Market sentiment

Posts on X, past 7 days

An AI-synthesised read of the highest-engagement posts about Enterprise Therapeutics on X, ranked by likes and reposts, corporate channels excluded.

Reading the room on X — pulling top posts and synthesizing themes…

Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour

See Enterprise Therapeutics’s full profile on Dealroom

Request a free trial to see the complete deal history, financials, people graph and growth signals.

Takes under a minute. Already use Dealroom? Log in.